Oral ulcers caused by hydroxyurea.

Oral ulcers are commonly linked to autoimmune conditions, infections, or nutritional deficiencies. Prior research has shown that antineoplastic agents may cause mucosal damage, though specific agents often remain unidentified. No prior work had resolved the connection between hydroxyurea and oral ulceration in hematological patients. This gap motivated a closer examination of drug-induced oral complications in chronic therapy. Established knowledge includes the role of hydroxyurea in managing myeloproliferative disorders. However, its potential to cause persistent oral ulcers remained unexplored in ENT literature. This paper introduces a novel clinical observation that expands the known side effect profile of hydroxyurea. The absence of prior documentation suggests a need for increased awareness among clinicians managing hematological conditions.

The aim of this case report is to document an unexpected adverse effect of hydroxyurea therapy in a patient with essential thrombocythaemia. The specific problem addressed is the lack of recognition of hydroxyurea as a potential cause of oral ulcers. The motivation stems from the patient's persistent symptoms despite standard diagnostic approaches. This case highlights the importance of drug history in diagnosing oral complications. The authors propose that hydroxyurea may contribute to mucosal damage independent of dose or treatment duration. The study seeks to raise awareness among ENT specialists and hematologists. The authors emphasize the need for a multidisciplinary approach in diagnosing unexplained oral lesions. This case serves as a cautionary example for clinicians managing chronic hematological conditions.

The study follows a single-patient case report format. Clinical evaluation included oral examination and patient history review. Laboratory tests confirmed the diagnosis of essential thrombocythaemia. The patient's medication history revealed long-term hydroxyurea use. No dose adjustments or recent changes in therapy were noted. The authors compared the patient's symptoms with known side effects of hydroxyurea. They reviewed ENT literature for similar reports and found none. The analysis focused on temporal and causal relationships between drug use and ulcer onset. The approach combined clinical observation with pharmacological literature review.

The patient presented with persistent oral ulcers unresponsive to standard treatments. Hydroxyurea was the only medication in use at the time of onset. Discontinuation of hydroxyurea led to resolution of symptoms. No other hematological complications were observed during the study period. The ulcers were localized to the oral mucosa and not systemic in nature. The authors found no prior documentation of this specific adverse effect in ENT literature. The onset was unrelated to cumulative dose or duration of therapy. This case provides the first evidence linking hydroxyurea to oral ulceration in hematological patients.

The authors conclude that hydroxyurea may cause persistent oral ulcers in patients with hematological conditions. This finding suggests a need for increased vigilance in monitoring patients on long-term hydroxyurea therapy. The authors propose that clinicians consider drug-induced ulcers in differential diagnoses. The study highlights the importance of medication history in diagnosing oral lesions. The authors emphasize that this complication is not dose-dependent or time-dependent. The report provides a cautionary example for ENT specialists and hematologists. The authors suggest that further case reports may help establish a clearer clinical pattern. This case expands the known adverse effect profile of hydroxyurea in clinical practice.